The luxury brand booked a 2% rise in comparable store sales, the first increase in two years. ...

GONZALES, La., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) today reported results for the second quarter fiscal year 2026, which ended September 28, 2025. Second Quarter Summary Net sales of $23.7 million compared to $24.5 million in the prior year quarterGross profit of 27.7 percent compared to 28.4 percent in the second quarter of fiscal 2025Net income grew to $1.2 million or $0.11 per share, up from $0.9 million or $0.08 per share in the prior year quarterDeclar ...

Core Insights - Interparfums, Inc. reported third-quarter 2025 results with earnings of $2.05 per share, a 6% increase from $1.93 in the prior year, surpassing the Zacks Consensus Estimate of $1.85 per share [3][9] - Consolidated net sales reached $429.6 million, reflecting a 1% increase from $424.6 million in the same period last year, driven by strong consumer interest in prestige and luxury fragrances [3][9] Financial Performance - The consolidated gross margin was 63.5%, down 40 basis points from the previous year, primarily due to increased U.S. import tariffs [4] - Selling, general and administrative expenses accounted for 38.2% of net sales, a decrease of 70 basis points year over year, with advertising and promotional expenditures at 15.3% of net sales [5] - Operating income was $108.6 million, with an operating margin of 25.3%, up from 25% in the prior year [5] Financial Health - The company ended the quarter with cash and cash equivalents of $110.4 million, long-term debt of $140 million, and total equity of $1,104.5 million [6] - A cash dividend of 80 cents per share was announced, payable on December 31, 2025, to shareholders of record as of December 15 [6] Future Outlook - Interparfums revised its 2025 sales outlook to $1.47 billion, a 1% year-over-year increase, down from the previous guidance of $1.51 billion [7][8] - The earnings per share forecast for 2025 is now $5.12, consistent with 2024 levels, compared to the earlier expectation of $5.35 [8]

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - The group, recognized as a bellwether for the U.K. retail sector, reported a 10.5% increase in total full-price sales [1] Group Performance - The total full-price sales increased by 10.5% [1]

Core Insights - Keurig Dr Pepper (KDP) reported better-than-expected quarterly results, driven by strong domestic sales and the acquisition of Ghost energy drinks [1][3][4] Financial Performance - The company achieved third-quarter adjusted earnings per share of $0.54, meeting analyst expectations, while revenue increased by 10.7% to $4.31 billion, surpassing estimates [2][4] - U.S. Refreshment Beverages sales rose by 14.4% to $2.7 billion, and U.S. coffee sales increased by 1.5% to $991 million, aided by price hikes for K-Cups [4] Growth Outlook - Keurig Dr Pepper raised its full-year sales growth forecast in constant currency to the high-single-digit percent range, up from a previous mid-single-digit percent increase [5][7] - The Ghost energy drink acquisition contributed 4.4 percentage points to volume/mix growth [4]

Core Insights - The market began 2025 positively but faced volatility due to tariff and geopolitical risks, with the Fed cutting rates by 25 basis points to 4.00–4.25% in September and signaling two more cuts for the year [1] - Despite inflation and rising unemployment, equities remain near record highs, driven by optimism over rate cuts, AI-driven earnings growth, and hopes for a soft landing [1] - Retail investors face challenges in stock selection amidst these conditions [1] Sales Growth as a Key Metric - Sales growth is preferred over earnings for evaluating stocks, as it reflects actual demand and provides visibility into a company's business model durability [3] - Companies that can grow revenues during economic downturns demonstrate pricing power and competitive advantages [3] - Constant sales growth leads to stronger cash flows, allowing for reinvestment, market expansion, or shareholder returns without excessive debt reliance [5] Stock Selection Criteria - Stocks with 5-Year Historical Sales Growth (%) greater than industry average and Cash Flow over $500 million are prioritized [6] - Additional metrics include P/S Ratio less than industry average, positive % Change in F1 Sales Estimate Revisions, Operating Margin greater than 5%, and Return on Equity (ROE) greater than 5% [7][8][9] Recommended Stocks - **Lamb Weston (LW)**: Expected sales growth rate of 1.3% for fiscal 2026, Zacks Rank 1 [12] - **Universal Health Services (UHS)**: Expected sales growth rate of 8.5% for 2025, Zacks Rank 2 [14] - **FirstEnergy Corp (FE)**: Expected sales growth of 6.6% in 2025, Zacks Rank 2 [14] - **NetEase, Inc. (NTES)**: Expected sales growth of 10.3% for 2025, Zacks Rank 2 [15] - **JPMorgan Chase & Co. (JPM)**: Expected sales growth of 2.1% in 2025, Zacks Rank 2 [16]

Core Insights - West Pharmaceutical Services, Inc. reported strong third-quarter 2025 earnings, with adjusted earnings of $1.96 per share, surpassing analyst estimates of $1.68 [1] - The company achieved net sales of $804.6 million, reflecting a year-over-year increase of 7.7%, with organic growth at 5.0%, exceeding the consensus of $787.93 million [1] Financial Performance - Proprietary Products sales reached $647.5 million, growing by 7.7% overall and 5.1% on an organic basis [2] - Contract-Manufactured Products sales were $157.1 million, up 8.0% overall and 4.9% on an organic basis [3] Outlook and Guidance - West Pharmaceutical raised its fiscal 2025 adjusted earnings guidance to a range of $7.06-$7.11 per share, compared to the previous guidance of $6.65-$6.85 and the analyst estimate of $6.77 [4] - The company also increased its 2025 sales guidance to $3.06 billion-$3.07 billion, up from $3.04 billion-$3.06 billion, against a consensus of $3.05 billion [4] - For the fourth quarter of 2025, net sales guidance is set between $790 million and $800 million, compared to the consensus of $796.19 million, with expected adjusted earnings per share of $1.81-$1.86 versus the consensus of $1.78 [5] Analyst Commentary - Analysts view the earnings update positively, noting that underlying demand levels are normalizing and execution is improving [6] - The stock is rated as Outperform, highlighting West's strong market position and dependable earnings and cash flow [6] - Following the earnings report, West Pharmaceutical shares rose by 10.50% to $306.08 [6]